Savara Inc.是罕见的疾病治疗开发商,报告季度损失,但库存增加。 Savara Inc., a rare disease treatment developer, reported a quarterly loss but saw its stock rise.

Savara Inc.是一家开发稀有呼吸道疾病治疗的公司,它报告每季度每股损失0.13美元,分析员的预期损失0.02美元。 Savara Inc., a company developing treatments for rare respiratory diseases, reported a quarterly loss of $0.13 per share, missing analysts' expectations by $0.02. 尽管出现亏损,该公司的股票价格还是上涨了0.04美元,达到2.82美元。 Despite the miss, the company's stock price increased by $0.04 to $2.82. Savara的管道包括AeroVanc、Molgradx和AIR001等毒品, 分析家给它一个“Moderate Buy”评级, 目标价格为8.83美元。 Savara's pipeline includes drugs like AeroVanc, Molgradex, and AIR001, and analysts have given it a "Moderate Buy" rating with a target price of $8.83.